Human TNFR2 extracellular domain (ECD) fragments (Accession Number P20333) corresponding to residues 1-119, 1-205 and 1-257 were sub-cloned into a mammalian transient expression vector, upstream of a FLAG-His 10 tag, and expressed in HEK293 cells. Purification from culture media supernatants was performed by affinity chromatography followed by size exclusion chromatography upon a HiLoad 16/60 Superdex 75 prep grade column (GE Healthcare, Bucks, UK).
TNFR2 expression by activated human lymphocytes
Cryopreserved PBMCs were defrosted and incubated in RPMI1640-based media supplemented where appropriate with 20 µg/mL PHA-P (Sigma) and 100 IU/mL IL-2 (Roche) for four days at 37°C/5% CO 2 . Cells were re-suspended, washed once with flow cytometry buffer, stained using mAbs directed against CD3-APC-H7 (clone SK7), CD4-PerCP-Cy5.5 (clone RPA-T4), CD8-BV711 (clone RPA-T8), CD25-APC (clone BC96), CD56-PECy7 (clone CMS5B), and TNFR2-FITC (clone 22235). Staining with Foxp3-PE mAb (clone PCH101) was performed according to manufacturer's instructions (Foxp3 fixation/permeabilisation kit, Ebioscience). Alternatively, PBMCs from HLA-A-positive donors with pre-defined reactivity to CMV pp65 (CTL) were defrosted, washed, and incubated in RPMI1640-based media supplemented where appropriate with 3 nM CMV peptide NLVPMVATV (Sigma) for five days. Staining with HLA-A/NLVPMVATV pentamers was performed according to manufacturer's instructions (ProImmune). Cells were finally washed, fixed and analysed by flow cytometry (FACSCantoII, BD Biosciences).
TNFR2 signalling assays
Jurkat E6.1 or HEK293 cells (ATCC) were transduced using replication-deficient lentivirus to express firefly luciferase via an NF-κB-responsive promoter, and further transfected using lipofectamine 2000 (Invitrogen) with a pcDNA3.1-based construct into which cDNA encoding human or mouse TNFR2 (NCBI sequences NM_001066.2 or NM_011610.3) flanked by 5ʹ GCCACC and 3ʹ TAATAA was inserted using BamHI and NotI (GeneArt, Invitrogen). Cells were selected for puromycin and geneticin resistance, cloned by limiting dilution or sorted for TNFR2 expression by flow cytometry. HEK293-based reporter assays were performed as for Jurkat-based assays, except using 3 × 10 4 HEK293 cells per well, and where appropriate 10 µg/mL goat anti-Armenian hamster IgG (Jackson Immunoresearch) was added to cells.
Analysis of publicly available RNAseq data
Publicly available RNAseq data (The Cancer Genome Atlas; http://cancergenome.nih.gov) were exported using Array Viewer (Omicsoft). For each gene analysed, fragments per kilobase squared (FPKM) values were summed for all transcripts, added to 0.1, and logarithmically transformed (base 2). Linear regression was performed using Prism 6.03 (GraphPad).
Measuring interactions between mAbs and mouse FcγRs
Surface plasmon resonance (SPR) measurements were performed on a Biacore T100 biosensor (GE Healthcare) at 25°C. Of note, ~3000 resonance units (RU) of monoclonal anti-His antibody (GE Healthcare, were immobilized on the CM3 surface by amine coupling (BIAapplications Handbook, GE Healthcare). The first flow cell served as a reference following one activation/deactivation cycle. The running buffer was HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% P20). Low-density surfaces with ≤100 RU of His-tagged mouse Fcγ receptors I-IV (FCGR1, FCGR2B, FCGR3, FCGR4 ) were generated to minimize mass transport. Doubling dilutions of mouse IgG1 and IgG2a isotype controls or TR75-54.7/ TR75-89 anti-TNFR2 (Biolegend) in HBS-EP in the concentration range 10KD to 0.1KD were injected over affinity-captured Fcγ receptors at 40 μL/min. Surfaces were regenerated with a 30 second pulse of 10 mM glycine, pH 1.5. All sensorgrams were double referenced. Biaevaluation 4.1 software (GE Healthcare) was used to derive kinetic parameters by fitting the data with a simple 1:1 binding model or to obtain the dissociation constant for fast interactions through the equilibrium binding model. + Treg cells were isolated from healthy donor PBMCs by negative selection followed by positive selection for CD25 expression. Treg cells were activated and expanded using anti-CD3/CD28 beads and IL-2 in the presence of rapamycin. Purity was assessed using flow cytometry by staining fixed/permeabilised cells for the Treg-specific transcription factor Foxp3. (B) Following expansion, activated/expanded Treg cells
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